Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, October 10, 2026

Back to today

From X

@StableBread

Fajasy on X

Alpayana, a private Peruvian mining group, asked for 19.9% of Magna Mining $MGMNF (TSX: $NICU) when management was “thinking something probably below 9.9,” per CEO Jason Jessup. On August 28, 2026, Alpayana, chaired by Alejandro Gubbins, bought 62,356,682 shares at CAD$2.25/share for US$99M. The US$99M more than quadrupled Magna’s cash at the time. Alpayana runs six underground mines in Peru and Mexico, most of them bought from other miners, including the Los Quenuales mines from Glencore $GLNCY in December 2022 and Sierra Metals, a copper-zinc miner, for ~US$176M in 2025. While it holds at least 10%, Alpayana can join future equity raises and top up after dilution, and it gets one board nominee or an observer. Jessup says Magna’s pre-deal plan already funded Levack, its flagship restart project, from cash and the cash flow of McCreedy West, its producing mine. So the US$99M mainly spares Magna from “delaying the startup construction at Crean Hill,” its permitted nickel mine, “by 1 or 2 years,” and gives it “a bit of a war chest” for acquisitions in Sudbury, Ontario, where its mines are. He also says Magna “could have five mines in production in 5 years and not have to ever do another financing again.” Neither restart study is out yet (both are due in the first half of October), so the claim rests on capital budgets investors haven’t seen. After the deal, Alpayana holds 19.9%, institutions 47.4%, retail investors 26.9%, and management and directors 5.8%. The institutional stake includes the 16.0% held by Dundee Corporation $DDEJF, a Toronto investment company.

Investor Letters

All letters

Golar LNG q2’26 Operational Update

Golar LNG ordered a $2.45 billion fourth FLNG vessel, targeting 3.5MTPA of capacity and $400 million in annual EBITDA under a 20-year…

GLNG $4.9B
Monte Independent Investment Research

What I’ve Been Up To

Cogent Communications and AI data-center bottlenecks feature in a newsletter update on recruiting, financial media and conference takeaways.

CCOI $515M
Stock Thoughts 2 clicks
BNTC · long

Benitec Biopharma INC

Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.

BNTC $314M
Value Investors Club

Solid Power Still Has Promise

Solid Power reported a $0.11 Q2 loss and $419.3 million of cash, with its electrolyte pilot line and BMW and SK On validation central to…

SLDP $528M
Quad 7 Capital 2 clicks

Publications we follow

Every publication on this site, hand-picked.

109 publications

Newsletters 92

YouTube 4

Blogs 12

Seeking Alpha 45 of 216

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

74 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.